Cirrhosis and Complications
programme overview

With over 1.5 billion people living with chronic liver disease worldwide, it is imperative that we stay informed on the latest developments in cirrhosis and portal hypertension, particularly acute-on-chronic liver failure. We have a wide range of exciting abstracts and data to present, including novel therapies and their implementation in clinical care.

The clinical part of the cirrhosis and complications track will feature the rivaroxaban trial in patients with cirrhosis. This trial will provide valuable insights into the safety concerns and prognostic views of coagulation in cirrhosis, providing participants with valuable information to take home and apply to their clinical practice.

In addition, the experimental part of the track will highlight future directions for research. With so many exciting new developments on the horizon, the EASL Congress 2023 is an excellent opportunity to stay up-to-date on the latest advancements in the field.

Participants will hear from experts who will discuss what will shape the field in future years. The sessions will also provide a great opportunity for delegate networking and discussion; and for industry stakeholders to showcase results.